Abstract. In the present study, we assessed the effect of the ethanolic extract of the seeds of Cassia obtusifolia (COE) on the learning and memory impairments induced by scopolamine or transient bilateral common carotid artery occlusion (2VO). In a study of the cholinergic dysfunction induced by scopolamine, single COE (25, 50, or 100 mg / kg, p.o.) administration significantly attenuated scopolamine-induced cognitive impairments as determined by the passive avoidance and Y-maze tasks (P<0.05) and also reduced escape-latency on the Morris water maze task (P<0.05). In the 2VO study, COE (50 mg / kg, p.o.) significantly reversed 2VO-induced cognitive impairments in mice by the passive avoidance and the Y-maze tasks (P<0.05). Moreover, COE (50 mg / kg, p.o.) also reduced escape-latency and prolonged swimming time in the target quadrant during a probe trial of the Morris water maze task (P<0.05). In an in vitro study, COE was found to inhibit acetylcholinesterase activity in a dose-dependent manner (IC 50 value: 81.6 µg / ml). Furthermore, COE also inhibited acetylcholinesterase activity in an ex vivo study. These results suggest that COE attenuates memory impairment induced by scopolamine or 2VO and that these effects are mediated by enhancing the cholinergic nervous system via acetylcholinesterase inhibition.
Introduction
Learning and memory are generated by an experience-dependent and long-lasting modification of the central nervous system. They involve activation by neurotransmitters, such as, acetylcholine, dopamine, and serotonin, of the receptor-linked enzymes that are responsible for the synthesis of intercellular messengers (1, 2) . A large number of studies have shown that the cholinergic system plays an important role in learning and memory (3) . Moreover, a loss of cholinergic neurons and reduced choline acetyltransferase activity in the cerebral cortex and hippocampus are consistent with findings in Alzheimer's disease (AD) (4 -6) . In fact, reduced cholinergic activity in the brains of individuals with AD provides the rationale for the development of acetylcholinesterase (AChE) inhibitors to treat the dementia associated with AD (7 -9) . The commonly prescribed AChE inhibitors, such as donepezil, rivastigmine, and galantamine were developed on this basis (10, 11) . Nevertheless, new drugs without adverse effects are urgently required (12) .
Ischemia-induced neuronal degeneration occurs in forebrain structures such as the striatum, cerebral cortex, and thalamus (13 -16) . Moreover, because hippocampal neuronal cell death is selectively vulnerable to ischemia, for example, global and focal ischemia, ischemic animal models have been widely used to investigate the mechanism of neuronal cell death and the action mechanisms of neuroprotective agents in vascular dementia (17 -20) . Learning and memory deficits are also observed in permanent or transient bilateral common carotid artery occlusion (2VO) murine models (21 -26) . Recently, Murakami et al. also studied memory impairments 2 weeks after 2VO in mice, and their findings suggested that the 2VO model is useful for investigating the effects of drugs and the mechanism of vascular dementia (27) .
The fruits of Cassia obtusifolia L. (Leguminosae) have been traditionally used in Korea, Japan, and China to treat eye inflammation, photophobia, and lacrimation (28) ; and it has been reported that Cassia obtusifolia has an anti-Helicobacter pylori effect (29, 30) . In addition, Cassia obtusifolia and its ingredients have estrogenic activities and inhibitory effects on the growth of Clostridium perfringens and Escherichia coli, on histamine release in mast cells, and on platelet aggregation (31 -34) . However, no attempts have been to investigate whether Cassia obtusifolia has anti-amnesic or mnemonic activities. The purpose of this study was to determine the effects of the ethanolic extract of the seeds of Cassia obtusifolia on memory impairment induced by scopolamine or 2VO in mice. Behavioral parameters were evaluated using the passive avoidance task, the Ymaze task, and the Morris water maze task in mice.
Materials and Methods

Animals
Male ICR mice (25 -30 g) were purchased from the Orient Co., Ltd., a branch of Charles River Laboratories (Seoul, Korea). Animals were housed 5 per cage with food and water available ad libitum and maintained under a constant temperature (23 ± 1°C) and humidity (60 ± 10%) under a 12-h light / dark cycle (light on 07:30 -19:30 h). All behavioral tasks were conducted between 10:00 h and 16:00 h. Animal treatment and maintenance were conducted in accordance with the Principle of Laboratory Animal Care (NIH publication No. 85-23, revised 1985) and the Animal Care and the Use Guidelines of Kyung Hee University, Korea.
Materials
Tacrine (9-amino-1,2,3,4-tetrahydroacridine hydrochloride), (−)scopolamine hydrobromide, acetylthiocholine iodide, and DTNB (5,5'-dithiobis [2-nitrobenzoic acid]) were purchased from the Sigma Chemical Co. (St. Louis, MO, USA). The seeds of Cassia obtusifolia were obtained from a herbal supplier in Seoul (Korea), and voucher specimens (KHUOPS-04-31) were deposited at the herbarium of the College of Pharmacy, Kyung Hee University (Seoul, Korea). The material was authenticated by Emeritus Professor Chang Soo Yook of the Department of Oriental Pharmaceutical Science, College of Pharmacy, Kyung Hee University. All other materials were obtained from normal commercial sources and were of the highest grade available.
Preparation of herbal extracts
The seeds of Cassia obtusifolia were extracted with 85% ethanol three times for 2 h under an ultrasonic apparatus. The ethanolic solution obtained was filtered, concentrated in a water bath under vacuum, frozen, and lyophilized (model FD-5N; Eyela, Tokyo) to yield the 85% ethanolic extract (defined as COE), which was then stored at −20°C until required (yield: 10.3%). COEs were standardized based on the contents of rubrofusarin 6-O-gentiobioside (molecular weight: 596.53) determined using reverse-phase high-performance liquid chromatography (Waters, Milford, MA, USA) equipped with a photodiode array detector (PAD). Separation was carried out using a Shiseido C 18 CAPCELL PAK column (5 µm, 4.6 × 250 mm; Shisheido, Tokyo) at 30°C under the following conditions: acetonitrile:water (15:85, v / v) (solvent A) and acetonitrile:water (25:75, v/ v) (solvent B) as mobile phase using a linear gradient at a flow rate of 1.0 ml / min. The detector wavelength was set at 254 nm. Rubrofusarin 6-O-gentiobioside was found in the COEs at a mean level of 0.44 ± 0.09% (n = 5) (Fig. 1) .
Surgical operation
ICR mice were anesthetized in a chamber with a mixture of N 2 O and O 2 (70:30) containing 1% isoflurane. 2VO was induced as described elsewhere (27) , with minor modification. Briefly, after making a median incision in the neck skin of a mouse, both common carotid arteries were exposed and occluded with aneurysm clips for 7 min. Body temperature was maintained at 37 ± 0.5°C throughout surgery by a heating pad (Biomed S.L., Alicante, Spain). Circulation was restored by removing the clips. Mice receiving the same surgical operation without clipping of the carotid arteries served as sham-operated controls.
Drug administration
COE was suspended in 10% Tween 80 solutions for use. Tacrine and scopolamine were dissolved in saline. In the scopolamine-induced memory impairment study (Experiment 1), COE (12.5, 25, 50, or 100 mg / kg, p.o.) or tacrine (10 mg / kg, p.o.) were given 1 h before the acquisition trial in the passive avoidance task, 1 h before a test trial in the Y-maze task, and 1 h before the first trial session every consecutive day in the water maze task. In the control group, vehicle solution (10% Tween 80, p.o.) was administered using the same time schedule. Memory impairment was induced by scopolamine treatment (1 mg / kg, i.p.) 30 min before each task. In the 2VO study (Experiment 2), COE (50 mg / kg, p.o.) or tacrine (10 mg/ kg, p.o.) was administered once a day from days 7 to 13 (for 1 week) after reperfusion and the last treatment was completed 1 h before each task. In the sham operated control group and 2VO control group, vehicle solution (10% Tween 80, p.o.) was administered using the same time schedule.
Passive avoidance task
Passive avoidance tasks were carried out as described elsewhere (35) . The apparatus (Gemini Avoidance System, San Diego, CA, USA) was equipped with identical illuminated and non-illuminated boxes with a guillotine door (5 × 5 cm). The illuminated compartment (20 × 20 × 20 cm) contained a 50 W bulb, and the floor of non-illuminated compartment (20 × 20 × 20 cm) was composed of 2-mm stainless steel rods spaced 1-cm apart. One hour after the last administration of each drug or vehicle, a mouse was gently placed in the illuminated compartment for the acquisition trial, and the door between the two compartments was opened 10-s later. When the mouse entered the dark compartment, the door automatically closed and an electrical foot shock (0.5 mA) of 3-s duration was delivered through the stainless steel rods. Twenty-four hours after this acquisition trial, the mouse was again placed in the illuminated compartment for a retention trial. The time taken for a mouse to enter the dark compartment after its door was opened was defined as latency time for both acquisition and retention trials. Latency for entering the dark compartment was recorded up to 300 s. If a mouse did not enter the dark compartment within 300 s, the mouse was removed and assigned a latency score of 300 s. For the investigation of the effect of COE on memory in unimpaired animals, COE alone were administered 1 h before the acquisition trial without treatment of scopolamine. The intensity of electrical foot shock was changed and set at 0.25 mA to avoid a ceiling effect in unimpaired animals. This lower intensity shock thus allowed for a behavioral window to see any potential enhancing effects of COE.
Y-maze task
The Y-maze is a three-arm horizontal maze (40-cmlong and 3-cm-wide with 12-cm-high walls) in which the arms are symmetrically disposed at 120° angles from each other. The maze floor and walls were constructed from dark opaque polyvinyl plastic as has been described previously (35) . Mice were initially placed within one arm, and the sequence (i.e., ABCCAB, etc.) and number of arm entries were recorded manually for each mouse over an 8-min period. An actual alternation was defined as entries into all three arms on consecutive choices (i.e., ABC, CAB, or BCA but not BAB). Maze arms were thoroughly cleaned between tasks to remove residual odors. One hour after the last administration of each drug or vehicle, mice were gently placed in the maze. The percentage of alternations was defined according to the following equation: % Alternation = [(Number of alternations) / (Total arm entries − 2)] × 100. The number of arm entries serves as an indicator of locomotor activity.
Morris water maze task
The Morris water maze is a circular pool with a featureless inner surface and a diameter and height of 90 and 45 cm, respectively. The pool was filled to a depth of 30 cm with water containing 500 ml of milk (20 ± 1°C). The tank was placed in a dimly lit, soundproof test room with various visual cues. A white platform (6 cm in diameter, 1-cm below the surface of the water) was then placed in one of the pool quadrants. The first experimental day was dedicated to swimming training for 60 s in the absence of the platform. During the four subsequent days, the mice were given two trial sessions per day with the platform in place. The time interval between each trial sessions was 30 min (36). For two trial sessions, mice were placed in the water facing the pool wall in one of the pool quadrants. The entry point was changed in a different order each day. Drug or vehicle was administered 1 h before the first training trial. When a mouse located the platform, it was permitted to remain on it for 10 s. If the mouse did not locate on the platform within 120 s, it was placed on the platform for 10 s. The animal was returned to its home cage and was allowed to dry up under an infrared lamp after each trial. During each trial session, the time taken to find the hidden platform (latency) was recorded using a video camera-based Ethovision System (Nodulus, Wageningen, The Netherlands). One day after the last training trial sessions, mice were subjected to a probe trial session in which the platform was removed from the pool, mice were allowed to swim for 120 s to search for it. A record was kept of the swimming time in the pool quadrant where the platform had been previously placed.
AChE activity assay
AChE activity assays were carried out using an acetylthiocholine iodide substrate by a colorimetric method, as described by Ellman et al. (37) . Whole mouse brains were homogenized in a glass Teflon homogenizer (Eyela) containing 10 volumes of homogenization buffer (12.5 mM sodium phosphate buffer, pH 7.0, 400 mM NaCl) and then centrifuged at 1,000 × g for 10 min at 4°C. The supernatant so obtained was used as source of enzyme for the assay. COE was initially dissolved in distilled water and diluted to various concentrations in Buffer A (100 mM sodium phosphate buffer, pH 8.0) immediately before use. An aliquot of diluted COE solution in Buffer A (1.5 ml) was then mixed with 2.6 ml of Buffer A, 20 µl of acetylthiocholine iodide solution (75 mM), and 100 µl of buffered Ellman's reagent (10 mM 5,5'-dithio-bis [2-nitrobenzoic acid] and 15 mM sodium bicarbonate) and reacted at room temperature for 30 min. Absorbance was measured at 410 nm immediately after adding the enzyme source (400 µl) to the reaction mixtures (OPTIZEN 2120UV; Fig. 1 . Representative HPLC chromatogram of standard rubrofusarin 6-O-gentiobioside (4 µg/ml) (A) and the ethanolic extract of seeds of Cassia obtusifolia (COE) (B). Rubrofusarin 6-O-gentiobioside was detected at around 30.7 min in this system. In the presented case, the concentration of rubrofusarin 6-O-gentiobioside in COE was 4.9 µg/ml. Mecasys Co., Ltd., Seoul, Korea). Readings were taken at 30-s intervals for 5 min. The concentration of COE required to inhibit AChE activity by 50% (IC 50 ) was calculated using an enzyme inhibition dose-response curve. Tacrine was used as a positive control. In an ex vivo study, mice were administered COE (50 mg / kg, p.o.) or tacrine (10 mg / kg, p.o.). Mice were decapitated 1 h after being administered COE or tacrine and brains were removed. AChE activities were determined as described above. In the control group, vehicle solution (10% Tween 80) was administered.
Statistics
Results are expressed as means ± S.E.M. In the passive avoidance task, acquisition and retention latencies were evaluated using the Kruskal-Wallis nonparametric test followed by Tukey's post hoc test. In the COE alone passive avoidance task, Y-maze task, probe trial of the Morris water maze task, and ex vivo AChE activity assay, data were analyzed by one-way analysis of variance (ANOVA) followed by the Tukey's post hoc test for multiple comparisons. In particular, group differences in the escape latency of the training trial session in the Morris water maze task were analyzed using two-way ANOVA with repeated measures. Differences were considered significant at the level of P<0.05.
Results
Experiment 1: the effects of COE on memory impairment induced by scopolamine Effect of COE on memory impairment induced by scopolamine in the passive avoidance test During acquisition trials, latency times were not different among the experimental groups by the acute treatments with COE with scopolamine [H (6) = 3.69, P = 0.85] (Fig. 2A) or COE alone [F (4, 46) = 0.972, P = 0.432] (Fig. 2B) . For retention trials, the KruskalWallis test revealed significant differences for latencies times in the acute treatments [H (6) = 47.39, P<0.001]. The step-through latency of scopolamine-treated mice was significantly shorter than that of vehicle-treated control mice (Fig. 2A, P<0.05 ). In tacrine with scopolamine-treated mice (a positive control group), step-through latency was significantly higher than that of the scopolamine-treated group (P<0.05). Moreover, the shorter step-through latencies induced by scopolamine were significantly attenuated by acute COE treatments (25, 50, or 100 mg / kg) versus the scopolamine-treated group (P<0.05). Furthermore, the stepthrough latencies of the groups treated with COE alone also increased more than those in the vehicle-treated control group [F (4, 46) = 3.921, P<0.05] (Fig. 2B) .
Effect of COE on memory impairment induced by scopolamine in the Y-maze test
Significant group effects on alternation behavior were observed for the acute COE treatment tests [F (6, 63) = 4.81, P<0.05] (Fig. 3A) . Spontaneous alternation of scopolamine-treated mice was significantly lower than that of vehicle-treated control mice (Fig. 3A,  P<0 .05), and the lowered spontaneous alternation induced by scopolamine was significantly reversed by COE for acute treatments (50 mg / kg; Fig. 3A, P<0.05) . Moreover, the effect of COE on spontaneous alternation behavior was similar to that of tacrine. Furthermore, the number of arm entries was similar across all experimental groups, showing that general locomotor activity was not affected by acute and subchronic COE treatments (Fig. 3B) .
Effect of COE on memory impairment induced by scopolamine in the Morris water maze test
The effect of COE (50 mg / kg, p.o.) on spatial learning was evaluated using the Morris water maze task. As shown in Fig. 4A within the target quadrant in the scopolamine-treated group were significantly lower than those in the vehicletreated control group (Fig. 4B, P<0.05) . Moreover, the shortened swimming time within the platform quadrant induced by scopolamine was significantly increased by COE or tacrine treatment (Fig. 4B, P<0 .05).
Experiment 2: the effects of COE on memory impairment induced by 2VO Effect of COE on memory impairment induced by 2VO in the passive avoidance test
During acquisition trials, latency times were similar across all experimental groups [H (3) = 3.65, P = 0.51]. However, the Kruskal-Wallis test revealed significant latency time differences during retention trials [H (3) = 31.21, P<0.001]. The step-through latency of the 2VO control group was significantly shorter than that of the sham control group during these trials (Fig. 5, P<0.05) , and the shorter step-through latency induced by 2VO was significantly reversed by COE treatment (50 mg / kg, p.o.) for 7 days (Fig. 5, P<0.05 ). In the tacrine-treated group, step-through latency was also significantly higher than that of the 2VO control group (P<0.05).
Effect of COE on memory impairment induced by 2VO in the Y-maze test
A significant group effect was observed on spontaneous alternation behavior [F (3, 36) = 12.25, P<0.001] (Fig. 6A) . Spontaneous alternation in the 2VO control group was significantly lower than that in the sham group (P<0.05). Moreover, the lowered levels of spontaneous alternation induced by 2VO were significantly reversed by COE (50 mg / kg, p.o.) for 7 days (Fig. 6A, P<0 .05), and this effect of COE on spontaneous alternation behavior was similar to that of tacrine. The total number of arm entries was similar for all experimental groups [F (3, 36) = 1.05, P = 0.621] (Fig. 6B) .
Effect of COE on memory impairment induced by 2VO in the Morris water maze test
The effect of COE (50 mg / kg, p.o.) on spatial learning impairment was evaluated using the Morris water maze test. As shown in Fig. 7A (Fig. 7A) , as did tacrine [F (1, 72) = 16.24, P<0.001] (Fig. 7A) . On the day following the final day of training trial sessions, swimming times within the target quadrant in the 2VO control group were significantly lower than those of the vehicle-treated control group (Fig. 7B P<0.05) . Moreover, reduced Fig. 7 . Effect of COE on performance in the training trials (A) and in the probe trial (B) of the Morris water maze task in transient bilateral common carotid artery occlusion (2VO)-induced memory deficits mice. Mice were orally treated with COE (50 mg /kg), the same volume of 10% Tween 80 solution, or tacrine (THA, 10 mg/kg) for 7 days; and COE (50 mg/kg), the same volume of 10% Tween 80 solution, or tacrine (THA, 10 mg/kg) was administered to mice 60 min before the first training trial of each day. In the training trials, each trial was carried out twice a day for 4 consecutive days. The second trial was carried out 30 min after the first trial. Escape latency was measured during a 2-min session. Data represent means ± S.E.M. (n = 10) (*P<0.05, compared with the sham group; # P<0.05, compared with the 2VO control group). Fig. 8 . Acetylcholine esterase (AChE) activity in an in vitro study (A) and an ex vivo study (B). Inhibition efficacy was expressed as percent inhibition of enzyme activity compared to the control value (100%). The concentration required for 50% enzyme inhibition (IC50) of COE was 81.6 µg/ml in the in vitro study. Each value represents a mean ± S.E.M. (n = 3). For the investigation of the effects of COE on AChE activity in the ex vivo study, animals (n = 5 per group) were treated with COE (50 mg/kg, p.o.), tacrine (THA, 10 mg/kg, p.o.), or the same volume of 10% Tween 80 solution and sacrificed at 1 h after each administration. AChE activities were determined as described in Materials and Methods. Data represent means ± S.E.M (*P<0.05 vs the vehicle control group).
swimming times within the target quadrant induced by 2VO were significantly increased by COE and by tacrine (Fig. 7B, P<0 .05).
Effect of COE on AChE activity
COE inhibited AChE activity in a dose-dependent manner with an IC 50 value of 81.6 µg/ ml (Fig. 8) . The IC 50 value of tacrine (positive control) was 334 ng / ml. COE (50 mg / kg, p.o.) also significantly inhibited AChE activity in an ex vivo experiment (P<0.05), and this effect was similar to that of tacrine (10 mg / kg, p.o.) .
Discussion
In the present study, it was found that single treatment with COE attenuated memory impairment induced by scopolamine or 2VO in the passive avoidance, the Ymaze, and the Morris water-maze test in mice. Furthermore, COE also inhibited AChE activity in a dosedependent manner, which suggests that the ameliorating effects of COE on memory dysfunction induced by scopolamine or 2VO may be associated with the inhibition of AChE.
Traditional Chinese medicine practitioners use the seeds of Cassia obtusifolia to relieve eye inflammation; and recently, phenolic compounds, alaternin, and norrubrofusarin glucose were isolated from Cassia species and were found to have potent peroxynitrite scavenging activities (38) . Moreover, Pickhardt et al. reported that emodin contained in Cassia species inhibits tau protein aggregation, which is a central feature in Alzheimer's disease (39) . These previous reports persuaded us to investigate the memory-enhancing properties of Cassia species.
Scopolamine, a muscarinic antagonist, shortened step-through latency in the passive avoidance task, demonstrating marked memory deterioration in mice. In the present study, reduced step-through latency by scopolamine was recovered to approximately 68% (50 mg / kg) by single treatments of COE. Moreover, tacrine, which has been used as an anti-amnesic drug, recovered step-through latency reduction by scopolamine treatment to 58% in the single treatment experiment, which is consistent with a previous report (40) . Previously, we observed that tacrine exhibited maximum effects at 10 mg / kg in the passive avoidance test (data not shown). According to the result of the present study, the potency of COE was comparable or superior to that of tacrine in the passive avoidance task. In order to confirm the effects of COE on other types of learning and memory, we used the Y-maze test because spontaneous alteration behavior in the Y-maze test is considered to be an indicator of short-term memory (41) . COE increased the spontaneous alternation reduction induced by scopolamine to approximately 90% (50 mg / kg) in the vehicle-treated control group, and this was similar to the effect of tacrine. In the Morris water maze learning task that is used to assess hippocampal-dependent spatial learning ability (42, 43) , escape latencies prolonged by scopolamine treatment were significantly shortened by COE (50 mg / kg) administration in training trial sessions. At the probe trial session, COE increased swimming time within the zone of the previously placed platform to approximately 97% of the vehicle-treated control group level, as did tacrine. Therefore, it appears reasonable to conclude that COE reverses the memory deficits induced by scopolamine. Moreover, COE alone also exhibited memory enhancing properties in the passive avoidance task. Interestingly, COE reversed the scopolamineinduced memory impairment in an inverted U-shaped dose-response curve fashion for single and subchronic treatment (data not shown) both in the passive avoidance task and in the Y-maze task. Braida et al. suggested that the activation of presynaptic autoreceptors might play a role in the reduced efficacy of cholinesterase inhibitors by enhancing acetylcholine release, which also resulted in an inverted U-shaped dose-response curve (44) . Although we did not determine the acetylcholine contents in synaptic clefts, we speculate that the inverted U-shaped dose-response curve of COE is due to its cholinomimetic properties (vide infra).
Several previous reports have suggested that transient ischemia causes hippocampal neuronal injuries in the CA1 and dentate gyrus regions and that these result in prominent cognitive impairments (13, 23, 26, 45, 46) . Recently, it was reported that mice with chronic cerebral hypoperfusion caused by 2VO exhibit learning impairments in a water maze task without marked histological alterations in the hippocampus (27) . Moreover, Wang et al. also found that transient cerebral hypoperfusion by 2VO in mice cause spatial cognitive impairment (47) . These reports suggest that learning and memory deficits in rodent 2VO models may provide a means of modeling vascular dementia (21, 22, 26) . In the present study, we observed that 2VO-treated mice exhibited serious memory impairments related to short and long term memory and spatial memory deficiencies, which is consistent with previous reports. However, step-through latency reduction by 2VO was recovered to approximately 63% of the sham group in the COE (50 mg / kg)-treated group. Tacrine (10 mg / kg), as a positive control, restored step-through latency to 43% of the vehicletreated control group. In addition, spontaneous alternation, which was reduced by 2VO, was recovered to approximately 94% of the sham group in the COE (50 mg / kg)-treated group. In the Morris water maze, the animals spent more time in the target quadrant, which indicates the animals acquired the Morris water maze task, showing spatial memory improvement (48) . Like tacrine, COE dramatically increased the swimming time within the target zone. Collectively, these behavioral studies suggest that COE ameliorates memory dysfunction induced by 2VO.
In Experiments 1 and 2, no differences in passive avoidance latencies during the acquisition trial and Ymaze total arm entries were observed between any of the groups, demonstrating that COE did not cause changes in general behavior or spontaneous locomotor activity (41) . Moreover, swimming speeds in the Morris water maze task were not different across any group (data not shown). In addition, no changes in spontaneous locomotor behavior were observed after COE treatment versus the vehicle-treated control group (data not shown). Taken together, the above findings indicate that the ameliorating effects of COE were not derived from behavioral changes.
Finally, to confirm the mechanism of action of COE, we assessed its inhibitory activity on acetylcholinesterase using mouse brain homogenates. Tacrine (positive control) inhibited acetylcholinesterase activity with an IC 50 of 334 ng / ml, which is consistent with previously published data (49) . Our in vitro study showed that COE also inhibited acetylcholinesterase activity in a dose-dependent manner with an IC 50 of 81.6 µg / ml. Moreover, COE significantly blocked AChE activity 1 h after administration in the ex vivo experiment. These results of the inhibition of AChE by COE could explain the anti-amnesic effect of COE on scopolamine-induced memory impairment, but it is unclear whether AChE inhibition contributes to COE amelioration of 2VO-induced memory impairment. Previously, it was reported that hypoperfusion by 2VO induced memory deficits in mice (50, 51) . In addition, we also reported that activated microglial cells and immunopositive cells for brain-derived neurotrophic factor (BDNF) were increased in the hippocampal area of 2VO mice and that the decrease of activated microglial cells and potentiation of BDNF expression may be involved in the anti-inflammatory and neuroprotective effects of a test preparation (50) . Therefore, we investigated whether COE affects microglial cells and the expression of BDNF in the hippocampal region of 2VO-treated mice. Administration of COE attenuated 2VO-induced increases in activated microglial cells and potentiated BDNF-positive cell immunoreactivity in 2VO-treated mice (data not shown). These results suggest that the memory ameliorating effects of COE in 2VO-treated mice may be derived from the antiinflammatory and neuroprotective properties of COE. However, it cannot be excluded that the inhibitory activity of COE on AChE plays a role in the memory enhancing effects of COE in 2VO-treated mice because stimulation of muscarinic acetylcholine receptors via the elevation of acetylcholine in the synaptic cleft attenuates spatial memory impairment by transient ischemia (52, 53) and ameliorates the transient ischemia-induced neuronal cell death (54) . Further studies are needed to elucidate the precise mechanisms underlying the neuroprotective activity of COE.
As described above, COE acted in the same manner as tacrine with respect to memory-related behavior, although the inhibitory effect on AChE was not as strong. The reasons why these two agents differ in terms of their in vivo and in vitro effects must be determined, here we can only speculate. First, it is possible that behavioral tasks could not discriminate between the effects of these tested drugs. Secondly, unidentified active compounds in COE may play key roles in the stimulation of the central cholinergic nervous system and also potently inhibit AChE. We are currently working on the isolation of active components in COE using an activity-guided fractionation approach.
In conclusion, the present study demonstrates that COE has the ability to ameliorate memory impairments due to a dysfunctional central cholinergic nervous system and hypoperfusion-induced memory deterioration and also demonstrates that these effects are mediated, in part, via AChE inhibition. Our present findings suggest that COE, or a constituent of COE, has therapeutic potential for the treatment of Alzheimer's disease and vascular dementia.
